“国家队”斥资超2000亿增持ETF，知名基金经理调仓路径各异

Core Viewpoint - The "national team" has significantly increased its investment in ETFs and equity assets, with an estimated total investment exceeding 207 billion yuan in the first half of the year, reflecting a strategic response to market volatility and a focus on structural opportunities [2][3][5]. Group 1: National Team's Investment Actions - In April, amidst increased volatility in the A-share market, the "national team" including Central Huijin and China Reform Holdings began to increase their holdings in ETFs and other equity assets [3]. - Central Huijin Asset Management has become the largest institutional investor in the Huatai-PineBridge CSI 300 ETF, increasing its holdings from 26.62 billion shares at the end of last year to 37.86 billion shares, representing a rise in shareholding ratio from 29.78% to 40.26% [3][4]. - The total estimated investment by the "national team" in ETFs for the first half of the year reached approximately 207.27 billion yuan, with significant contributions from various ETFs [5][6]. Group 2: Fund Managers' Adjustments - In the second quarter, over 57% of active equity funds increased their stock positions, with some funds raising their equity allocation by more than 30% [8]. - Notable fund managers like Zhang Kun have adjusted their portfolios, increasing their holdings in liquor stocks despite a general reduction in the food and beverage sector [9]. - Liu Gesong has focused on increasing allocations to Hong Kong stocks and non-bank financials, with significant investments in companies like Xiaomi and New Oriental Education [9]. Group 3: Sector Focus and Trends - The innovative drug sector has seen increased interest from fund managers, with significant allocations to companies involved in cutting-edge technologies and international collaborations [10]. - Fund managers are optimistic about the potential for domestic innovative drugs to gain international recognition and market share, driven by ongoing clinical trials and partnerships with multinational pharmaceutical companies [10].